Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

Saved in:
Bibliographic Details
Title: Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Authors: Gibb A; The Christie NHS Foundation Trust, Manchester, UK., Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J
Source: Haematologica [Haematologica] 2013 Apr; Vol. 98 (4), pp. 611-4. Date of Electronic Publication: 2012 Oct 12.
Publication Type: Journal Article
Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1592-8721
DOI:10.3324/haematol.2012.069393